Advice

The marketing authorisation for albiglutide (Eperzan) has been withdrawn.

Medicine details

Medicine name:
albiglutide (Eperzan)
SMC ID:
1024/15
Indication:
Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Endocrine system
Submission type
Full
Status
Withdrawn
Date advice published:
11 January 2016